基于西米达的希夫基混合支架:开发用于阿尔茨海默病的多向药物的有希望的方法
Rafaqat Hussain1, Shoaib Khan2, Hayat Ullah3
1Department of Chemistry, Hazara University, Mansehra 21120, Pakistan.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
合成了新的西米达希夫基,并对其酶抑制进行了测试. 化合物3,5和9显示出对乙胆酶 (AChE) 和丁胆酶 (BuChE) 的强烈抑制,表明潜在的治疗应用.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 酶抑制研究 研究 酶抑制研究
背景情况:
- 阿尔茨海默病的特点是由于神经递质失衡导致认知能力下降.
- 乙胆酶 (AChE) 和丁胆酶 (BuChE) 是参与乙胆代谢的关键酶.
- 开发用于ACHE和BuChE的新型抑制剂是阿尔茨海默病的关键治疗策略.
研究的目的:
- 为了合成和表征基于西米达的新型希夫基衍生物.
- 评估这些衍生物对ACHE和BuChE的抑制潜力.
- 通过分子对接建立结构-活动关系.
主要方法:
- 18种基于本齐米达的希夫基衍生物的合成.
- 使用1H NMR,13C NMR和HREI-MS.进行结构阐明.
- 在体外酶抑制测定对ACHE和BuChE.
- 分子对接研究,以预测结合相互作用.
主要成果:
- 所有合成的衍生品都显示出对AChE和BuChE的显著抑制.
- 化合物3,5和9表现出特别强大的抑制活性.
- 对于AChE的IC50值在123.9 ± 10.20至342.60 ± 10.60μM之间,而对于BuChE则在131.30 ± 9.70至375.80 ± 12.80μM之间.
- 分子对接支持实验结果,阐明了潜在的结合模式.
结论:
- 基于西米达的希夫基代表了开发ACHE和BuChE抑制剂的有前途的化合物类.
- 化合物3,5和9是作为阿尔茨海默病潜在治疗剂的进一步研究的领先候选物.
- 结构-活性关系研究为设计更强大的抑制剂提供了宝贵的见解.
更多相关视频
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.4K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
相关概念视频
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
